Newsroom

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced it will host an investor call and live webcast on Monday, November 9, 2026, at 8:00 am ET to review topline results from Part B of its randomized, double-blind, placebo-controlled registration-directed Phase 3 clinical trial (Study ‘302’) evaluating VDPHL01, a proprietary, ext...

LITTLE ROCK, Ark.--(BUSINESS WIRE)--Onterris (NYSE: ONT) a global environmental solutions company solving complex challenges for planet and progress, today announced the acquisition of EcOz Environmental Consultants, a provider of end-to-end environmental and advisory services that support clients in the responsible development, operation, and rehabilitation of projects through practical, science-based solutions for managing regulatory, environmental, and stakeholder risks. Based in the Norther...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced new, expanded data from the Phase 2 SOLSTICE trial evaluating monthly subcutaneous administration of elebsiran and tobevibart in adults with chronic hepatitis delta (CHD). These data include new analyses presented in oral sessions at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2026, in Denver, Colorado. “We are seeing rapid viral suppression that deepens over time, alon...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced positive topline results from the pivotal Phase 3 ECLIPSE 1 trial evaluating monthly subcutaneous administration of elebsiran and tobevibart in adults with chronic hepatitis delta (CHD). Topline results were presented in an oral session at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2026, in Denver, Colorado. “For people living with CHD, the goal is not simply to reduce...

LOS ANGELES--(BUSINESS WIRE)--ROCK Investors Have Opportunity to Join Gibraltar Industries, Inc. Fraud Investigation with SBS Law...

ORLANDO, Fla.--(BUSINESS WIRE)--A type of cellular therapy originally developed to treat cancer is showing promise as a potential treatment for people with difficult-to-treat lupus, according to a new study from researchers at Hospital for Special Surgery (HSS). Known as chimeric antigen receptor (CAR) T-cell therapy, the approach is increasingly being investigated for the treatment of systemic lupus erythematosus (SLE). The study, CAR T-Cell Therapy in SLE: A Pooled Analysis, was presented tod...

SAN DIEGO--(BUSINESS WIRE)--The case alleges Everest Group and its executives made false and/or misleading statements to investors....

RENTON, Wash.--(BUSINESS WIRE)--Recall is of Fresh To You Sausage, Egg & Cheese Biscuit Sandwiches in OR and WA that have the potential to be contaminated with Listeria monocytogenes...

أنطاليا، تركيا--(BUSINESS WIRE)--بينما يستعد قادة العالم للاجتماع في أنطاليا لحضور مؤتمر الأطراف COP31، تحذر منظمة 350.org من أن العالم لا يستطيع تحمل عقد آخر من التأخير في الانتقال بعيدًا عن الوقود الأحفوري. يبدأ مؤتمر الأمم المتحدة للمناخ وسط أكبر أزمة للوقود الأحفوري في التاريخ ويواجه الناس في جميع أنحاء العالم آثارًا مناخية مدمرة بشكل متزايد بينما تواصل شركات الوقود الأحفوري تحقيق أرباح فاحشة.يتناول هذا البيان الصحفي الوسائط المتعددة. يمكنك الاطلاع على البيان كاملاً هنا: https://www.business...

ANTALYA, Turquia--(BUSINESS WIRE)--Às vésperas da COP31, que reunirá líderes mundiais em Antalya para discutir ações de enfrentamento à crise climática, a 350.org alerta que o mundo não pode arcar com mais uma década de atraso na transição para longe dos combustíveis fósseis. A conferência climática da ONU começa em meio à maior crise de combustíveis fósseis da história, enquanto pessoas em todo o mundo enfrentam impactos climáticos cada vez mais devastadores e as empresas do setor continuam a...